Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of pirfenidone in systemic sclerosis-related interstitial lung disease
2013-001353-28Phase 2Completed
- Sponsor
- InterMune
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pirfenidone in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) (2 arms), sponsored by InterMune. Primary endpoint: Safety and tolerability (AEs and SAEs). Started Jul 2013; status: completed.
02
Drugs
pirfenidone
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2013-001353-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001353-28.